Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Anna Szlachcic"'
Autor:
Karolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, Jakub Szymczyk, Jacek Otlewski, Anna Szlachcic
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer treatments is fibroblast
Externí odkaz:
https://doaj.org/article/916c9edb3c4d499ab88c5169dc5b691f
Publikováno v:
FEBS Open Bio, Vol 9, Iss 5, Pp 914-924 (2019)
Overexpression of fibroblast growth factor receptor 1 (FGFR1) is a common aberration in lung and breast cancers and has necessitated the design of drugs targeting FGFR1‐dependent downstream signaling and FGFR1 ligand binding. To date, the major gro
Externí odkaz:
https://doaj.org/article/9800d58bc1d14d0cb946ac6d79c38544
Autor:
Nadinath B Nillegoda, Antonia Stank, Duccio Malinverni, Niels Alberts, Anna Szlachcic, Alessandro Barducci, Paolo De Los Rios, Rebecca C Wade, Bernd Bukau
Publikováno v:
eLife, Vol 6 (2017)
Hsp70 participates in a broad spectrum of protein folding processes extending from nascent chain folding to protein disaggregation. This versatility in function is achieved through a diverse family of J-protein cochaperones that select substrates for
Externí odkaz:
https://doaj.org/article/a20258da37e549069a38cb1d780a7bdf
Autor:
Anna Szlachcic, Martyna Sochacka, Aleksandra Czyrek, Lukasz Opalinski, Daniel Krowarsch, Jacek Otlewski, Malgorzata Zakrzewska
Publikováno v:
Cells, Vol 8, Iss 8, p 899 (2019)
Fibroblast growth factor 1 (FGF1) has been shown to interact with integrin αvβ3 through a specific binding site, involving Arg35 residue. The FGF1 mutant (R35E) with impaired integrin binding was found to be defective in its proliferative response,
Externí odkaz:
https://doaj.org/article/0c367a45b8d1447bb3ca64eca4bdc6e9
Autor:
Julia Chudzian, Anna Szlachcic, Malgorzata Zakrzewska, Miroslawa Czub, Marcin Pustula, Tad A. Holak, Jacek Otlewski
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 9, p 2470 (2018)
Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor ty
Externí odkaz:
https://doaj.org/article/0e4b08cafd534cea8ed256e82a54412f
Autor:
Karolina Weronika Świderska, Anna Szlachcic, Łukasz Opaliński, Małgorzata Zakrzewska, Jacek Otlewski
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 7, p 2098 (2018)
In the rapidly developing field of targeted cancer therapy there is growing interest towards therapeutics combining two or more compounds to achieve synergistic action and minimize the chance of cancer resistance to treatment. We developed a fibrobla
Externí odkaz:
https://doaj.org/article/c1a9073f2f8f42cca8c0d64f0f63a292
Autor:
Karolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, Anna Kocyła, Jakub Szymczyk, Jacek Otlewski, Anna Szlachcic
Publikováno v:
Molecular pharmaceutics. 19(5)
With a wide range of available cytotoxic therapeutics, the main focus of current cancer research is to deliver them specifically to the cancer cells, minimizing toxicity against healthy tissues. Targeted therapy utilizes different carriers for cytoto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e19b478f35ea34aea11c2d6a7aafce
https://pubmed.ncbi.nlm.nih.gov/35389227
https://pubmed.ncbi.nlm.nih.gov/35389227
Autor:
Jacek Otlewski, Karolina Jendryczko, Anna Szlachcic, Mateusz Adam Krzyscik, Jakub Szymczyk, Jakub Rzeszotko
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer treatments is fibroblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b60f7af4288584394b19e3f55751e0
http://europepmc.org/articles/PMC8636100
http://europepmc.org/articles/PMC8636100
Publikováno v:
FEBS Open Bio
Overexpression of fibroblast growth factor receptor 1 (FGFR1) is a common aberration in lung and breast cancers and has necessitated the design of drugs targeting FGFR1-dependent downstream signaling and FGFR1 ligand binding. To date, the major group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e65bfa782131b73e75ff18ff2554214
https://doi.org/10.1002/2211-5463.12618
https://doi.org/10.1002/2211-5463.12618
Autor:
Daria Nawrocka, Aleksandra Sokolowska-Wedzina, Karolina Jendryczko, Mateusz Adam Krzyscik, Natalia Porębska, Marta Pozniak, Malgorzata Zakrzewska, Lukasz Opalinski, Jacek Otlewski, Anna Szlachcic
Publikováno v:
Journal of Visualized Experiments.
Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc5a9e6cdae65d48d0fa9f5cab41080
https://doi.org/10.3791/61918
https://doi.org/10.3791/61918